Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 2/20 | 0.54 |
| ▸ | ACP1 | P24666 | 2/20 | 0.54 |
| ▸ | OGG1 | O15527 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GBA1 | P04062 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911813 | 0.81 | ADORA2A (0.60) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL4913903 | 0.81 | KCNN2 (0.59) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL4912379 | 0.81 | KCNN2 (0.59) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL29051975 | 0.81 | KCNN3 (0.59) | CCR4ADORA3ADORA2AKDM4EHSD17B10 | |
| SCHEMBL4908801 | 0.81 | KCNN2 (0.59) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL4911365 | 0.79 | KCNN2 (0.57) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL24649760 | 0.77 | ACP1 (0.68) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL14256631 | 0.75 | CCR4 (0.71) | CCR4PDE5AACP1KDM4EHSD17B10 | |
| SCHEMBL4907646 | 0.74 | CCR4 (0.54) | CCR4PDE5AACP1OGG1TLR7 | |
| SCHEMBL4910336 | 0.74 | ALDH1A1 (0.51) | CCR4PDE5AACP1TLR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | claimed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | claimed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | claimed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | claimed |
| EP-1861388-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097441-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-21 | — | — | WO | claimed |
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | disclosed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | disclosed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | disclosed |
| EP-1861388-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097441-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | KCND2, KCNN3, KCNJ2 | CCR4 3341/4885PDE5A 904/4885ACP1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.